<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16779">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095509</url>
  </required_header>
  <id_info>
    <org_study_id>2012-004599-21</org_study_id>
    <nct_id>NCT02095509</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Enoxaparin in Intensive Care Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <authority>Finland: Finnish Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the pharmacokinetics of the thromboprophylactic agent enoxaparin in critically
      ill patients by comparing plasma anti-factor Xa activity when enoxaparin is administered
      either as a continuous intravenous infusion or subcutaneous bolus once daily.

      To investigate possible ongoing coagulation by coagulation markers during antithrombotic
      therapy with standard doses of enoxaparin
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Plasma anti-factor Xa level</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Change in plasma anti-factor Xa levels between baseline and 72 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Venous thromboembolism</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>If clinically suspected a compression ultrasound will be done</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Bleeding</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major and minor bleeding events will be reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous enoxaparin 40 mg every 24 hours for three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg enoxaparin daily as continuous intravenous infusion for three days (72 hours)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Drug class: Low-molecular weight heparin</description>
    <arm_group_label>Subcutaneous Enoxaparin</arm_group_label>
    <arm_group_label>Intravenous Enoxaparin</arm_group_label>
    <other_name>Klexane (sanofi-Aventis Oy, Finland)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 to 70 years

          -  Body Mass Index between 18-30 kg/m2

          -  Critically ill patients requiring intensive care and pharmacological
             thromboprophylaxis

          -  Expected to remain in the ICU for at least 72 h

          -  Written informed consent obtained from the patient or his/her legal representative.

        Exclusion Criteria:

          -  Other indications for anticoagulant therapy than thromboprophylaxis

          -  Intracranial haemorrhage or central neurosurgical operation within three months prior
             to the admission

          -  Disseminated intravascular coagulation (DIC) according to the international society
             on Thrombosis and Haemostasis criteria

          -  Known heparin induced thrombocytopenia (HIT), or hypersensitivity to enoxaparin or
             heparin

          -  Treatment with enoxaparin or any other low-molecular weight heparin (LMWH) or heparin
             within 24 hours prior to ICU admission. If patient has received thromboprophylactic
             dose of LMWH within 24-72 hours before ICU admission inclusion can be done if
             measured anti-factor Xa level is &lt;0.1 IU/ml at the time of admission

          -  Any long-term anticoagulant medication, expect low-dose aspirin

          -  Major bleeding within the last week unless definitively treated

          -  Blood platelet count &lt;50, P-thromboplastin time (TT) &lt;40% , international normalized
             ratio (INR) &gt;1.7

          -  Glomerular filtration rate less than 50 ml/min/1.73 m2 estimated from serum
             creatinine by applying Cockcroft-Gault equation  or chronic dialysis

          -  HIV, hepatitis B virus, or hepatitis C virus infection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne Kuitunen, PhD</last_name>
    <phone>+358 3 311 65544</phone>
    <email>anne.kuitunen@pshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <state>Pirkanmaa</state>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Kuitunen, PhD</last_name>
      <phone>+358 3 311 65544</phone>
      <email>anne.kuitunen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Annukka Yl√∂nen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital, Meilahti</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miia Valkonen, PhD</last_name>
      <email>miia.valkonen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Miia Valkonen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
